Clinical Trial Update: Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating adding sorafenib to standard primary therapy in newly diagnosed acute myeloid leukemia patients under 60 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Technische Universität Dresden | Conditions: Acute Myeloid Leukemia (AML) | Phase 2 | Status: COMPLETED